Rationally Modified Antimicrobial Peptides from the N-Terminal Domain of Human RNase 3 Show Exceptional Serum Stability.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
12 08 2021
Historique:
pubmed: 4 8 2021
medline: 25 2 2023
entrez: 3 8 2021
Statut: ppublish

Résumé

Multidrug resistance against conventional antibiotics poses an important threat to human health. In this context, antimicrobial peptides (AMPs) have been extensively studied for their antibacterial activity and promising results have been shown so far. However, AMPs tend to be rather vulnerable to protease degradation, which offsets their therapeutic appeal. Here, we demonstrate how replacing functional residues in the antimicrobial region of human RNase 3-also named eosinophil cationic protein-by non-natural amino acids increases stability in human serum. These changes were also shown to reduce the hemolytic effect of the peptides in general terms, whereas the antimicrobial activity was reasonably preserved. Digestion profiles enabled us to design new peptides with superior stability and lower toxicity that could become relevant candidates to reach clinical stages.

Identifiants

pubmed: 34342438
doi: 10.1021/acs.jmedchem.1c00795
pmc: PMC8483441
doi:

Substances chimiques

Anti-Bacterial Agents 0
Antimicrobial Cationic Peptides 0
Eosinophil Cationic Protein EC 3.1.27.-
RNASE3 protein, human EC 3.1.27.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11472-11482

Références

Chem Rev. 2002 Dec;102(12):4501-24
pubmed: 12475199
J Mol Graph. 1996 Feb;14(1):51-5, 29-32
pubmed: 8744573
Bioorg Med Chem. 2013 Jan 1;21(1):205-14
pubmed: 23199484
Biomacromolecules. 2010 Aug 9;11(8):1983-90
pubmed: 20690710
Methods Mol Biol. 2004;278:353-78
pubmed: 15318003
J Biomol NMR. 2013 Jul;56(3):227-41
pubmed: 23728592
Virulence. 2010 Sep-Oct;1(5):440-64
pubmed: 21178486
J Biomol NMR. 1995 Sep;6(2):135-40
pubmed: 8589602
Respir Res. 2011 Jan 14;12:10
pubmed: 21235798
J Bacteriol. 2000 Jul;182(14):4077-86
pubmed: 10869088
Biochem Pharmacol. 1999 Dec 1;58(11):1775-80
pubmed: 10571252
Trends Microbiol. 2015 Sep;23(9):524-6
pubmed: 26338444
Nat Protoc. 2008;3(2):163-75
pubmed: 18274517
Biochem J. 2013 Nov 15;456(1):99-108
pubmed: 23962023
Curr Opin Immunol. 1998 Feb;10(1):41-4
pubmed: 9523109
FEBS Lett. 2010 May 3;584(9):1840-7
pubmed: 19837069
Science. 1992 Aug 21;257(5073):1064-73
pubmed: 1509257
J Phys Chem B. 2017 May 11;121(18):4713-4721
pubmed: 28413881
Folia Microbiol (Praha). 2014 May;59(3):181-96
pubmed: 24092498
Biol Chem. 2012 Aug;393(8):801-15
pubmed: 22944682
Drug Discov Today. 2010 Jan;15(1-2):40-56
pubmed: 19879957
Eur J Biochem. 2002 Jan;269(1):307-16
pubmed: 11784325
Mol Biosyst. 2007 May;3(5):317-35
pubmed: 17460791
Chemistry. 2020 May 12;26(27):5970-5981
pubmed: 32073728
Trends Microbiol. 2019 Apr;27(4):323-338
pubmed: 30683453
Lancet Infect Dis. 2013 Dec;13(12):1057-98
pubmed: 24252483
Nat Commun. 2018 Apr 16;9(1):1490
pubmed: 29662055
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6313-25
pubmed: 27527084
Curr Pharm Des. 2010;16(28):3185-203
pubmed: 20687878
Antimicrob Agents Chemother. 2000 Dec;44(12):3317-21
pubmed: 11083634
Trends Biotechnol. 2015 Aug;33(8):462-70
pubmed: 26088007
Protein Pept Lett. 2014 Apr;21(4):330-5
pubmed: 24164264
Int J Mol Sci. 2016 Aug 05;17(8):
pubmed: 27527162
Arch Pharm Res. 2018 Nov;41(11):1092-1097
pubmed: 30361948
Expert Opin Biol Ther. 2017 Jun;17(6):663-676
pubmed: 28368216
Biochem J. 2009 Jul 15;421(3):425-34
pubmed: 19450231
Blood. 2003 Nov 1;102(9):3396-403
pubmed: 12855582
Protein J. 2013 Aug;32(6):456-66
pubmed: 23925670
J Pept Sci. 2011 Dec;17(12):812-7
pubmed: 21956793
J Med Chem. 2011 Jul 28;54(14):5237-44
pubmed: 21696142
J Appl Microbiol. 2012 Oct;113(4):723-36
pubmed: 22583565
Sci Rep. 2015 Dec 18;5:18355
pubmed: 26680226
Nat Rev Cancer. 2007 Oct;7(10):800-8
pubmed: 17851543
J Biol Chem. 2007 Jul 6;282(27):19653-65
pubmed: 17452329
FEBS J. 2010 Apr;277(7):1713-25
pubmed: 20180804
Nat Rev Microbiol. 2005 Mar;3(3):238-50
pubmed: 15703760
Crit Rev Microbiol. 2012 May;38(2):168-81
pubmed: 22239733
J Immunol. 1989 Jun 15;142(12):4428-34
pubmed: 2656865
Front Immunol. 2018 May 16;9:1012
pubmed: 29867984
Anal Biochem. 2000 Dec 15;287(2):252-60
pubmed: 11112271

Auteurs

Daniel Sandín (D)

Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Cerdanyola del Vallès 08193, Spain.

Javier Valle (J)

Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, Barcelona 08003, Spain.

Belén Chaves-Arquero (B)

Departamento de Química-Física Biológica, Instituto de Química Física Rocasolano (IQFR-CSIC), Serrano 119, Madrid 28006, Spain.

Guillem Prats-Ejarque (G)

Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Cerdanyola del Vallès 08193, Spain.

María Nieves Larrosa (MN)

Servei de Microbiologia, Hospital Universitari Vall d'Hebron, Barcelona 08035, Spain.
Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Cerdanyola del Vallès 08193, Spain.

Juan José González-López (JJ)

Servei de Microbiologia, Hospital Universitari Vall d'Hebron, Barcelona 08035, Spain.
Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Cerdanyola del Vallès 08193, Spain.

María Ángeles Jiménez (MÁ)

Departamento de Química-Física Biológica, Instituto de Química Física Rocasolano (IQFR-CSIC), Serrano 119, Madrid 28006, Spain.

Ester Boix (E)

Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Cerdanyola del Vallès 08193, Spain.

David Andreu (D)

Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, Barcelona 08003, Spain.

Marc Torrent (M)

Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Cerdanyola del Vallès 08193, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH